Search

Author/Creator Evans, T.R.J.

1. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma. (December 2022)

Authors:
Sweis, R.; Garralda, E.; Saavedra Santa Gadea, O.; Moore, K.N.; Davar, D.; Hamid, O.; Segal, N.H.; Evans, T.R.J.; Dar, M.; Yuan, Y.; Collins, L.; Kirk, P.B.; Karakuzu, O.; Lopez, J.S.; Melero, I.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022)

Authors:
Di Giacomo, A.M.; Santangelo, F.; Amato, G.; E. Simonetti, ; Graham, J.; Lahn, M.; van der Veen, L.; Hammett, T.; Pickering, C.A.; Durini, M.; Ziyang, T.; Lakshmikanth, T.; Brodin, P.; Occhipinti, M.; Simonelli, M.; Carlo-Stella, C.; Santoro, A.; Spiliopoulou, P.; Evans, T.R.J.; Maio, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. (October 2022)

Authors:
Fontana, E.; Williams, A.; Falchook, G.; Lakhani, N.; Evans, T.R.J.; Gondi, V.; Iwamoto, F.; McKean, M.; Symeonides, S.; Butowski, N.; McLaren, A.; Henry, J.; Buerki, R.; Rotolo, J.; Capiaux, G.; Michel, R.; Kaesshaefer, S.; Wiegert, E.; Bexon, A.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S82
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search